NEW YORK (GenomeWeb) – An international group, led by researchers from the University of Toronto, has developed a next-generation sequencing-based assay to predict the risk of relapse in patients with acute myeloma leukemia (AML) who have received chemotherapy and a bone marrow transplant.

The team said that the tool could offer clinicians a prognostic indicator for long-term patient survival following transplant surgeries, insights that could be used to refine drug treatment.